A systematic review of the antipsychotic properties of cannabidiol in humans

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 153-161

  Iseger, Tabitha A ^a   Bossong, Matthijs G ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotic; Cannabidiol; Cannabis; Psychosis; Schizophrenia

Indexed keywords

CANNABIDIOL; DRONABINOL; HALOPERIDOL; PLACEBO; NEUROLEPTIC AGENT;

ABSENCE OF SIDE EFFECTS; BRAIN FUNCTION; BRIEF PSYCHIATRIC RATING SCALE; CANNABIS USE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CORPUS STRIATUM; DELUSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HIPPOCAMPUS; HUMAN; NEUROIMAGING; NEUROPHARMACOLOGY; NEUROPSYCHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; TREATMENT DURATION; BRAIN; DRUG EFFECTS; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; BRAIN; CANNABIDIOL; HUMANS; PSYCHOTIC DISORDERS;

EID: 84923164414     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.033     Document Type: Review

References (81)

1. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 2004, 184:110-117.
2. Bhattacharyya S., Fusar-Poli P., Borgwardt S., Martin-Santos R., Nosarti C., O'Carrol C., Allen P., Seal M., Fletcher P., Crippa J.A., Giampietro V., Mechelli A., Atakan Z., McGuire P. Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: a neural basis for the effects of cannabis sativa on learning and psychosis. Arch. Gen. Psychiatry 2009, 66:442-451.
3. Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., Nosarti C., O'Carroll C.M., Seal M., Allen P., Mehta M.A., Stone J.M., Tunstall N., Giampietro V., Kapur S., Murray R.M., Zuardi A.W., Crippa J.A., Atakan Z., McGuire P.K. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
4. Bhattacharyya S., Crippa J.A., Allen P., Martin-Santos R., Borgwardt S., Fusar-Poli P., Rubia K., Kambeitz J., O'Carroll C., Seal M.L., Giampietro V., Brammer M., Zuardi A.W., Atakan Z., McGuire P.K. Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry 2012, 69:27-36.
5. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134:845-852.
6. Borgwardt S.J., Allen P., Bhattacharyya S., Fusar-Poli P., Crippa J.A., Seal M.L., Fraccaro V., Atakan Z., Martin-Santos R., O'Carroll C., Rubia K., McGuire P.K. Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol. Psychiatry 2008, 64:966-973.
7. Bossong M.G., Niesink R.J.M. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog. Neurobiol. 2010, 92:370-385.
8. Bossong M.G., Jansma J.M., van Hell H.H., Jager G., Kahn R.S., Ramsey N.F. Default mode network in the effects of δ9-tetrahydrocannabinol (THC) on human executive function. PLoS One 2013, 8:e70074.
9. Bossong M.G., Jager G., Bhattacharyya S., Allen P. Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Curr. Pharm. Des. 2014, 20:2114-2125.
10. Bossong M.G., Jansma J.M., Bhattacharyya S., Ramsey N.F. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or δ9-tetrahydrocannabinol. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 52:53-69.
11. Ceccarini J., De Hert M., Van Winkel R., Peuskens J., Bormans G., Kranaster L., Enning F., Koethe D., Leweke F.M., Van Laere K. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 2013, 79:304-312.
12. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.-T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
13. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 2005, 57:594-608.
14. Dalton W.S., Martz R., Lemberger L., Rodda B.E., Forney R.B. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin. Pharmacol. Ther. 1976, 19:300-309.
15. Dalton V.S., Long L.E., Weickert C.S., Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 2011, 36:1620-1630.
16. De Petrocellis L., Ligresti A., Moriello A.S., Allarà M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011, 163:1479-1494.
17. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
18. Demirakca T., Sartorius A., Ende G., Meyer N., Welzel H., Skopp G., Mann K., Hermann D. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2011, 114:242-245.
19. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T.R., Handley R., Luzi S., Russo M., Paparelli A., Butt A., Stilo S.A., Wiffen B., Powell J., Murray R.M. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 2009, 195:488-491.
20. Di Forti M., Sallis H., Allegri F., Trotta A., Ferraro L., Stilo S.A., Marconi A., La Cascia C., Reis Marques T., Pariante C., Dazzan P., Mondelli V., Paparelli A., Kolliakou A., Prata D., Gaughran F., David A.S., Morgan C., Stahl D., Khondoker M., Maccabe J.H., Murray R.M. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 2014, 1-9.
21. Englund A., Morrison P.D., Nottage J., Hague D., Kane F., Bonaccorso S., Stone J.M., Reichenberg A., Brenneisen R., Holt D., Feilding A., Walker L., Murray R.M., Kapur S. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 2012, 27:19-27.
22. Foti D.J., Kotov R., Guey L.T., Bromet E.J. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am. J. Psychiatry 2010, 167:987-993.
23. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., Seal M., Surguladze S.A., O'Carrol C., Atakan Z., Zuardi A.W., McGuire P.K. Distinct effects of δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 2009, 66:95-105.
24. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
25. Glass M., Dragunow M., Faull R.L.M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
26. Goode D.J., Manning A.A., Middleton J.F., Williams B. Fine motor performance before and after treatment in schizophrenic and schizoaffective patients. Psychiatry Res. 1981, 5:247-255.
27. Green B., Kavanagh D., Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003, 22:453-460.
28. Green B., Young R., Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br. J. Psychiatry 2005, 187:306-313.
29. Hallak J.E.C., Machado-de-sousa J.P., Crippa J.A.S., Sanches R.F., Trzesniak C., Chaves C., Bernardo S.A., Cecílio S., Zuardi A.W. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev. Bras. Psiquiatr. 2010, 32:56-61.
30. Hallak J.E.C., Dursun S.M., Bosi D.C., de Macedo L.R.H., Machado-de-Sousa J.P., Abrão J., Crippa J.A.S., McGuire P., Krystal J.H., Baker G.B., Zuardi A.W. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:198-202.
31. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 1991, 11:563-583.
32. Hermann D., Sartorius A., Welzel H., Walter S., Skopp G., Ende G., Mann K. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol. Psychiatry 2007, 61:1281-1289.
33. Hill M.N., McLaughlin R.J., Morrish A.C., Viau V., Floresco S.B., Hillard C.J., Gorzalka B.B. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009, 34:2733-2745.
34. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., Frank R.A. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 2001, 58:322-328.
35. Jenko K.J., Hirvonen J., Henter I.D., Anderson K.B., Zoghbi S.S., Hyde T.M., Deep-Soboslay A., Innis R.B., Kleinman J.E. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr. Res. 2012, 141:185-188.
36. Juckel G., Roser P., Nadulski T., Stadelmann A.M., Gallinat J. Acute effects of delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr. Res. 2007, 97:109-117.
37. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
38. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A. Cannabidiol interferes with the effects of delta9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 1974, 28:172-177.
39. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 2012, 35:529-558.
40. Klein C., Karanges E., Spiro A., Wong A., Spencer J., Huynh T., Gunasekaran N., Karl T., Long L.E., Huang X.F., Liu K., Arnold J.C., McGregor I.S. Cannabidiol potentiates δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 2011, 218:443-457.
41. Ledent C. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
42. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict. Biol. 2008, 13:264-275.
43. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10:1665-1669.
44. Leweke F.M., Schneider U., Radwan M., Schmidt E., Emrich H.M. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol. Biochem. Behav. 2000, 66:175-181.
45. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., Klosterkötter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2:e94.
46. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry. 1994, 51:273-279.
47. McGorry P.D., Nelson B., Amminger G.P., Bechdolf A., Francey S.M., Berger G., Riecher-Rössler A., Klosterkötter J., Ruhrmann S., Schultze-Lutter F., Nordentoft M., Hickie I., McGuire P., Berk M., Chen E.Y., Keshavan M.S., Yung A.R. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009, 70:1206-1212.
48. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008, 30:67-76.
49. Moore T.H.M., Zammit S., Lingford-Hughes A., Barnes T.R.E., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
50. Morgan C.J., Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192:306-307.
51. Morgan C.J., Schafer G., Freeman T.P., Curran H.V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study. Br. J. Psychiatry 2010, 197:285-290.
52. Morgan C.J., Gardener C., Schafer G., Swan S., Demarchi C., Freeman T.P., Warrington P., Rupasinghe I., Ramoutar A., Tan N., Wingham G., Lewis S., Curran H.V. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol. Med. 2012, 42:391-400.
53. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 2006, 172:556-560.
54. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008, 153:199-215.
55. Pijlman F.T., Rigter S.M., Hoek J., Goldschmidt H.M., Niesink R.J. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict. Biol. 2005, 10:171-180.
56. Polich J. P300 in clinical applications: meaning, method, and measurement. Am. J. EEG Technol. 1991, 31:201-231.
57. Potter D.J., Clark P., Brown M.B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 2008, 53:90-94.
58. Rais M., Cahn W., van Haren N., Schnack H., Caspers E., Hulshoff Pol H., Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry 2008, 165:490-496.
59. Reid M.J., Bornheim L.M. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem. Pharmacol. 2001, 61:1357-1367.
60. Roser P., Juckel G., Rentzsch J., Nadulski T., Gallinat J., Stadelmann A.M. Effects of acute oral delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur. Neuropsychopharmacol. 2008, 18:569-577.
61. Roser P., Gallinat J., Weinberg G., Juckel G., Gorynia I., Stadelmann A.M. Psychomotor performance in relation to acute oral administration of delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:284-292.
62. Schubart C.D., Sommer I.E.C., van Gastel W.A., Goetgebuer R.L., Kahn R.S., Boks M.P.M. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr. Res. 2011, 130:216-221.
63. Schubart C.D., Sommer I.E.C., Fusar-Poli P., de Witte L., Kahn R.S., Boks M.P.M. Cannabidiol as a potential treatment for psychosis. Eur. Neuropsychopharmacol. 2014, 24:51-64.
64. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J. Psychiatry Neurosci. 2007, 32:30-52.
65. Stadelmann A.M., Juckel G., Arning L., Gallinat J., Epplen J.T., Roser P. Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neurosci. Lett. 2011, 496:60-64.
66. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts": what we know in 2008 part 1: overview. Schizophr. Res. 2008, 100:4-19.
67. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110:1-23.
68. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 76:1-23.
69. United Nations Office on Drugs and Crime World Drug Report 2013 2013, United Nations, New York, United States.
70. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
71. Veen N.D., Selten J., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161:501-506.
72. Winton-Brown T.T., Allen P., Bhattacharyya S., Bhattacharrya S., Borgwardt S.J., Fusar-Poli P., Crippa J.A., Seal M.L., Martin-Santos R., Ffytche D., Zuardi A.W., Atakan Z., McGuire P.K. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 2011, 36:1340-1348.
73. Wong D.F., Kuwabara H., Horti A.G., Raymont V., Brasic J., Guevara M., Ye W., Dannals R.F., Ravert H.T., Nandi A., Rahmim A., Ming J.E., Grachev I., Roy C., Cascella N. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010, 52:1505-1513.
74. Zanettini C., Panlilio L.V., Alicki M., Goldberg S.R., Haller J., Yasar S. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front. Behav. Neurosci. 2011, 5:57.
75. Zavitsanou K., Garrick T., Huang X.-F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:355-360.
76. Zuardi A.W., Karniol I.G. Pharmacological interaction between 9-tetrahydrocannabinol and cannabidiol, two active constituents of Cannabis sativa. Ciênc. Cult. 1984, 36:386-394.
77. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76:245-250.
78. Zuardi A.W., Morais S.L., Guimarães F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56:485-486.
79. Zuardi A.W., Hallak J.E.C., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., Crippa J.A.S. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 2006, 20:683-686.
80. Zuardi A.W., Crippa J.A.S., Hallak J.E.C., Pinto J.P., Chagas M.H.N., Rodrigues G.G.R., Dursun S.M., Tumas V. Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 2009, 23:979-983.
81. Zuardi A.W., Crippa J.A.S., Hallak J.E.C., Bhattacharyya S., Atakan Z., Martin-Santos R., McGuire P.K., Guimarães F.S. A critical review of the antipsychotic effects of cannabidiol: 30years of a translational investigation. Curr. Pharm. Des. 2012, 18:5131-5140.